Healthcare Sales & Marketing Network News: Gilenya

Searching News Database: Gilenya

HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 11 Jul 2017
Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 6 Mar 2017
BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Regenerative Medicine Neurology Personnel

HSMN NewsFeed - 8 May 2014
Charleston Laboratories, Inc., Bolsters Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Nov 2012
AIMM Therapeutics Appoints Former Head Novartis Research Institutes Jan de Vries CEO, and John Womelsdorf VP Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Apr 2011
Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Sep 2010
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.